Inactive Wnt/β‐catenin pathway in conventional high‐grade osteosarcoma
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most common malignant bone tumour, with a peak incidence in children and young adolescents, suggesting a role of rapid bone growth in its pathogenesis. The Wnt/β‐catenin pathway plays a crucial role in skeletal development and is indispensable for osteoblasts' lineage determination. Previous studies suggesting an oncogenic role for the Wnt/β‐catenin pathway in osteosarcoma were based on cytoplasmic staining of β‐catenin or the detection of one component of this pathway. However, those approaches are inappropriate to address whether the Wnt/β‐catenin pathway is functionally active. Therefore, in this study, we examined nuclear β‐catenin expression in 52 human osteosarcoma biopsies, 15 osteoblastomas (benign bone tumours), and four human osteosarcoma cell lines by immunohistochemistry. Furthermore, we modulated Wnt/β‐catenin pathway activity using a GIN (GSK3β inhibitor) and evaluated its effect on cell growth and osteogenic differentiation. Absence of nuclear β‐catenin staining was found in 90% of the biopsies and all osteosarcoma cell lines, whereas strong nuclear β‐catenin staining was observed in all osteoblastomas. Wnt‐luciferase activity was comparable to the negative control in all osteosarcoma cell lines. GIN stimulated the Wnt/β‐catenin pathway, as shown by translocation of β‐catenin into the nucleus and increased Wnt‐luciferase activity as well as mRNA expression of AXIN2, a specific downstream target gene. Stimulation of the Wnt/β‐catenin pathway by GIN significantly reduced cell proliferation in the cell lines MG‐63 and U‐2‐OS and enhanced differentiation in the cell lines HOS and SJSA‐1, as shown by an increase in alkaline phosphatase (ALP) activity and mineralization. In contrast with the oncogenic role of the Wnt/β‐catenin pathway in osteosarcoma as previous studies suggested, here we demonstrate that this pathway is inactivated in osteosarcoma. Moreover, activation of the Wnt/β‐catenin pathway inhibits cell proliferation or promotes osteogenic differentiation in osteosarcoma cell lines. Our data suggest that loss of Wnt/β‐catenin pathway activity, which is required for osteoblast differentiation, may contribute to osteosarcoma development. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595 · cited 2×
“In summary, our studies strongly suggest that Wnt signalling may be inactive in osteosarcoma, which is in contrast with its oncogenic role, as previous studies have reported and shown in many other cancer types [47].”
BackgroundResultHigh Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591
Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Patched acts catalytically to suppress the activity of Smoothened
Taipale, J., Cooper, M. K., Maiti, T., & Beachy, P. A. (2002) · Nature · doi:10.1038/nature00989 · Cited by 794
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · cited 1×
“Limited improvement in survival has been achieved over the past 20 years, regardless of intensifying or modifying chemotherapy [1,2].”
BackgroundSequential roles of Hedgehog and Wnt signaling in osteoblast development
Hu, H., Hilton, M. J., Tu, X., Yu, K., Ornitz, D. M., & Long, F. (2005) · Development · doi:10.1242/dev.01564 · Cited by 682
Cited by
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“In conventional high-grade OS, the Wnt/β-catenin pathway is inhibited while reactivation of this pathway has been demonstrated to suppress cancer cell proliferation [276].”
BackgroundNew molecular insights into osteosarcoma targeted therapy
Yang, J., & Zhang, W. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283622c1b · Cited by 262
Gorlick, R., & Khanna, C. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.77 · Cited by 157
Martins-Neves, S. R., Paiva-Oliveira, D. I., Fontes-Ribeiro, C., Bovée, J. V. M. G., Cleton-Jansen, A.-M., & Gomes, C. M. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.004 · Cited by 115
Self-citationSurface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
PosthumaDeBoer, J., Piersma, S. R., Pham, T. V., van Egmond, P. W., Knol, J. C., Cleton-Jansen, A. M., van Geer, M. A., van Beusechem, V. W., Kaspers, G. J. L., van Royen, B. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.578 · Cited by 73
“…family member Frizzled-7 receptor that is involved in survival, migration and disease progression in OS (Guo et al, 2007b, 2008; Chen et al, 2008; Cai et al, 2010; McQueen et al, 2011); integrin-a4, described to be of influence on cell survival in OS (Marco et al, 2003) and integrin-b4 that has…”
BackgroundSelf-citationPrognostic significance of the expression of HER family members in primary osteosarcoma
Wang, S., Zhong, G., Wang, X., Yu, F., Weng, D., Wang, X., & Lin, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8931 · Cited by 20
Denzer, L., Muranyi, W., Herold, R., Stump-Guthier, C., Ishikawa, H., Sticht, C., Schroten, H., Schwerk, C., & Weichert, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041779 · Cited by 3
“Finally, a specific inhibitor of GSK-3 β (SB216763; 10 µ M) was employed that had also been used previously [28].”
Metadata
- Authors
- Cai, Y., Mohseny, A. B., Karperien, M., Hogendoorn, P. C., Zhou, G., & Cleton‐Jansen, A.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2009-10-30
- Volume
- 220
- Issue
- 1
- Pages
- 24-33
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2111048208
- Cited by
- 155
- References
- 13
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.